Healthtech_Leaders_horizontal white

 

Main agenda

Big pharma, business models, partnerships, reimbursement, funding & more

BOOK TICKETS

 

Day 1 – Wednesday 3rd May

09:00 LSX Welcome Address

Nadia Konneh, Senior Conference Director, Healthtech Lead, LSX


09:10 Big Pharma’s Global Digital Health Priorities and Strategy

As pharma moves from a product to a platform focus, the highly strategic approach requires a focus on new infrastructure and services to meet the needs of customers in new ways. The chief heads of digital at top pharma companies will have a high-level discussion about their global digital health strategy, how they plan to improve the use of new tech across their companies, manage data better, foster successful partnerships and collaboration, and generally encouraging the digital health ecosystem worldwide.

  • What are your digital priorities (across the entire value chain)?
  • How do you plan to manage data better?
  • A look into the benefits of mining internal datasets vertically and what new insights can this yield?
  • Insights into the challenges and opportunities of external collaboration and partnering with digital disruptors
  • How do you develop and deploy patient/ physician facing solutions as quickly as possible?

Davidek Herron, Chief Digital Officer, Roche
Cristina Durán
, Chief Digital Health Officer, R&D, AstraZeneca

Davidek Herron, Chief Digital Officer, RocheCristina Durán, Chief Digital Health Officer, R&D, AstraZeneca


09:50 Keynote Panel: Scaling Digital Health Companies and Creating Commercially Viable Business Models

With countries and regions across the globe developing and enforcing a plethora of overlapping (and in some cases confusing) regulations on data privacy, protection, and localization, and with EU regulations such as the Digital Markets Act, it is making it difficult for digital health companies to scale up. With profitability also a priority, it is imperative for digital health companies to develop commercially viable business models. This discussion will highlight case studies and best practices for global expansion in the EU & US.

  • How the EU’s fragmented digital markets make it hard for companies to scale and what can be done?
  • Is the EU prioritising regulation over innovation?
  • How do we make Europe a destination of choice for scale up?
  • Hot to drive global expansion into the US market
  • Best practices for successful digital health business models in Europe and the US

Mark Jenkins, Co-Founder, Oviva
Matt Fujisawa, VP, Global Head of Corporate Development, KRY
Konstantin Mehl, CEO, Kaia Health
Rebecca Gwilt, Partner, Nixon Gwilt Law

Mark Jenkins, Co-Founder and Medical Director, Oviva-1Matt Fujisawa, Global Head of Corporate Development, KRY-1Konstantin Mehl, Founder and CEO, Kaia HealthRebecca Gwilt, Partner, Nixon Gwilt Law


10:30 Morning Break


11:10 Panel: The Big Pharma Digital Transformation Journey - Entering a New Era of Digital Health at Scale

  • The realities of digitally transforming a pharma company and the way they work
  • Sharing the wins – what has worked well in your digital transformation journey?
  • How can we go further in making pharma’s processes more user-centric and efficient?
  • The importance of digital innovation to better serve patients, physicians and improve outcomes
  • Digitalising and improving treatment algorithms– how can you even digitalise this?

Søren Smed Østergaard, VP, Digital Health, Novo Nordisk
Christian Hein, Global Head of Digital Transformation & Innovation Execution, Novartis
Joerg Corsten, Senior Digital Transformation & Innovation Director, Roche

Søren Smed Østergaard, Vice President and Head of Digital Health, Novo Nordisk-1Christian Hein, VP Global Head of Digital Transformation & Innovation Execution, NovartisJoerg Corsten, Senior Digital Transformation & Innovation Director, Roche


12:00 Panel: Creating Successful Digital Health-Pharma Partnerships and Collaborations

  • Partnering with Pharma – what are commercial leaders looking for?
  • The need for new collaboration models
  • Overcoming roadblocks in digital health and DTx partnerships and collaborations
  • How to create win-win partnerships between big pharma and digital innovators
  • How to implement AI, machine learning and other emerging technologies into worldwide innovation
  • What is the M&A market looking like?
Mats Berggren, Head of Search & Evaluation, Digital Innovation & External R&D, Merck
Sophie Park, Managing Director, Digital Health, Bayer Pharmaceuticals
Susanne Gruber, VP Pharma Partnerships, Sidekick Health
Sarah Beeby, Managing Director, Liva Healthcare
Valerie HeppDigital and PHC Partnering Europe and Asia Lead, Roche

Mats Berggren, Director, Digital Business Innovation & External Collaboration Models, M-Digital Lead, Merck KGaASophie ParkSusanne Gruber, VP Pharma Partnerships, Sidekick HealthSarah Beeby, Managing Director, Liva HealthcareValerie Hepp, Digital and PHC Partnering Europe, Roche


12:50 Lunch Break


14:00 Panel: Getting a Digital Therapeutic Approved and Reimbursed in Europe

  • Case studies from DTx companies that have therapeutics approved in Europe
  • How to succeed in a fragmented European regulatory landscape
  • An overview of the main DTx reimbursement frameworks and practical examples on getting DTx reimbursed
  • The challenges of demonstrating evidence across different regulatory and reimbursement requirements
  • Commercialisation models: what is working, what is not
Megan Coder, VP of Global Policy, Digital Therapeutics Alliance
Francesca Domenech Wuttke, Founder & CEO, nen health
Hannes Klopper, CEO, Co-Founder, HelloBetter
Eveline Van Keymelen, Partner, Latham & Watkins

Megan Coder, Vice President of Global Policy, Digital Therapeutics AllianceFrancesca Domenech Wuttke, Founder and CEO, nen healthHannes Klopper, CEO, Co-Founder, HelloBetter Eveline Van Keymelen, Partner, Latham & Watkins


14:50 Panel: Evaluating the Digital Therapeutics Investment Landscape Over the Past Year

  • How do we get to scale?
  • M&A and consolidation: What are the trends?
  • Discussing the willingness of investors to fund non-organic growth strategies
  • What has been the effect of digital therapeutics companies going public?
  • Has adoption been consistent with expectations? (Usage, prescription, revenues generated)
Marc Sluijs, Founder, DigitalHealth.Network
Ingrid Teigland Akay, Managing Partner, Hadean Ventures
Edward Kliphuis, Partner, Sofinnova Partners
Christian Lautner, Managing Partner, Heal Capital
Lana Ghanem, Managing Director, Hikma Ventures

Marc Sluijs, Founder, DigitalHealth.NetworkIngrid Teigland Akay, Managing Partner, Hadean VenturesEdward Kliphuis, Partner, Sofinnova PartnersChristian Lautner, Managing Partner, Heal CapitalLana Ghanem, Managing Director, Hikma Ventures


15:40 Afternoon Break


16:20 Panel: Assessing the Progress in the Women’s Health Space

  • Can we match the level of deal flow seen in general health?
  • What funding opportunities are out there? Where are the funding gaps?
  • Insights on how to raise capital - What are investors looking for from women’s health companies?
  • Building a product that is consumer friendly and medical grade
  • Closing the education gap and improving health literacy

Evie Mulberry, Managing Partner, Astia Fund
Priya Oberoi, Managing Director, Goddess Gaia Ventures
Keren Leshem, CEO, OCON Healthcare
Elizabeth Bailey, Managing Director, RH Capital

Evie Mulberry, Managing Partner, Astia FundPriya Oberoi, Managing Director, Goddess Gaia VenturesKeren Leshem, CEO, OCON HealthcareElizabeth Bailey, Managing Director, Rhia Ventures 300x


17:00 Closing Keynote Panel- The Healthtech Funding Slump: Are We on The Way Back Up?

  • Lessons learned from 2021 and 2022 VC investments in healthtech
  • An overview of the European digital health investment activity over the past year
  • Digital health M&A activity in Europe and US
  • Assessing the current valuation environment
  • Notable transactions and growing digital health companies in Europe and US
  • What’s next for healthtech funding, finance and investment?

Christoph Kausch, Managing Partner, MTIP
Samuel Levy, Founding Partner, Lauxera Capital Partners
Robert Garber, Partner, 7wire ventures
Clara Campàs, Managing Partner, Asabys
Marta Gaia Zanchi, Managing Partner, Nina Capital

Christoph Kausch, Managing Partner, MTIPSamuel Levy, Founding Partner, Lauxera Capital PartnersRobert Garber, Partner, 7WireVenturesClara Campàs, Managing Partner, AsabysMarta Gaia Zanchi, Founder and Managing Partner, Nina Capital


17:40 Drinks Reception


18:30 Networking Party


Day 2 – Thursday 4th May

09:00 LSX Welcome Address

Nadia Konneh, Senior Conference Director, Healthtech Lead, LSX


09:10 Keynote Panel: Is Population Health Management Going to Save Healthcare?

Population health management (PHM) is a whole system approach which aims to improve the health of an entire population, while reducing health inequalities. Digital technologies can be used in PHM to enable earlier treatment and diagnosis, large-scale clinical trials, and collect evidence to assess how effective new treatment pathways are.

  • How can health systems, payers and digital health companies can work together to support population health management?
  • Exploring the relationship between service redesign and analytics
  • Population health management strategies to reduce health disparities
  • Genomics as a population health management tool in the transition to value-based care
  • A spotlight on innovative digital health companies that are building solutions for population health management

Mark Davies, Chief Medical Officer, IBM
Geraint Lewis, Director of Population Health, Microsoft
Shirlene Oh, Chief Strategy and Population Health Officer, Hampshire Hospitals NHS Foundation Trust

Mark Davies, Chief Medical Officer, IBMGeraint Lewis, Director of Population Health, MicrosoftShirlene Oh, Chief Strategy & Population Health Officer, Hampshire Hospitals NHS Foundation Trust


09:50 Driving Greater Adoption of HealthTech Innovation Within the NHS and Ensuring a Patient Centric Experience

HealthTech innovation is integral to resolving the long-term challenges faced by the NHS, but many providers in the sector are having difficulty adopting and realising their full potential. What can we do to drive greater adoption and enhance the experience for patients and clinicians?

  • Outlining the challenges of HealthTech adoption and how we can overcome this
  • How can HealthTech innovation solve the long-term challenges faced by healthcare systems like the NHS?
  • Aligning patient/physician perspectives and empowering providers with the full potential of HealthTech solutions
Moderator: Tom Houston, Healthcare – Client Partner, Gobeyond Partners 
Emma Bouché, Head of Healthcare, Webhelp

Michael Macdonnell, Global Head of Healthcare, Huma
Toby Basey-Fisher,
CEO & Founder, Entia

Tom Houston, Healthcare – Client Partner, Gobeyond Partners Emma Bouche, Head of Healthcare, Webhelp UKMichael Macdonnell, Global Head of Healthcare, HumaToby Basey-Fisher, CEO & Founder, Entia


10:30 Morning Break


11:10 Panel: Leveraging Real-World Evidence and Real-World Data

  • How is RWE being used and regulated?
  • Assessing the adoption of RWD/RWE in R&D and commercially
  • How is RWD being used post product approval? How are products being improved upon?
  • How have technological advancements helped in scaling the use of RWD/RWE?

Dan Vahdat, CEO, Huma
Alex Simpson, Global Access RWE Lead, Roche

Dan Vahdat, CEO, Huma 300xAlex Simpson, Global Access RWE Lead, Roche


12:00 Panel: Making Value-Based Healthcare a Reality

  • What exactly do we mean by “value-based healthcare”?
  • Is value-based healthcare a sustainable business model?
  • How do you demonstrate value to regulators?
  • Paying for value and not volume – connecting value to outcomes
  • How can digital health drive value-based healthcare?

Assaf Barnea, Managing Partner, Sanara Capital & Sanara Ventures
Joe Stringer, Partner, Octopus Ventures
Jeffrey Scott, President & Chief Medical Officer, Integra Connect
Andrei Soran, CEO, Pipeline Health

Assaf Barnea, CEO, Sanara VenturesJoe Stringer, Partner, Octopus VenturesDr Jeffrey Scott, President and Chief Medical Officer, Integra ConnectAndrei Soran, CEO, Pipeline Health


12:50 Lunch Break


14:00 The race to the Exit: Are Europe’s Digital Health Start-Ups Keener Than Ever to Be Acquired?

Has the healthtech sector emerged unscathed from the market downturn? There has been an increase of digital health start-ups that have been acquired or bought out in the past year, and many more are looking to exit. Hear from companies and investors about why this is and the impact of the external funding environment on digital health start-ups willingness to exiting.
  • Profitability is priority-the shift in what investors are looking
  • The decrease in valuations and cheque sizes
  • The need for more capital and the long timeframes to scale profitability for digital health start-ups
  • A digital health M&A wave – insight from start-ups who have gone through the acquisition process with larger companies
Ranjan Singh, Co-Founder, HealthHero
Elina Halatcheva, Managing Partner, Brightcap Ventures
Laurence Fontinoy, CEO & Co-Founder, WOOM
Gregoire Guillet, Chief Business and Value Officer, WeHealth Digital Medicine - Servier

Ranjan Singh, Co-Founder, HealthHeroElina Halatcheva, Managing Partner, Brightcap VenturesLaurence Fontinoy, CEO & Cofounder, WOOM Health 300xGregoire Guillet, Chief Business & Value Officer – WeHealth Digital Medicine, Servier


14:40 Panel: Digital Mental Health 2.0 – Scaling Behavioural Healthtech

  • Funding has poured into behavioural health technology start-ups and innovations these last few years, but is it sustainable?
  • What are the key challenges in scaling mental health start-ups?
  • Building a scalable mental health business model
  • Taking an evidence-based approach to mental healthcare tech innovation

Georgi Natchev, CEO, Digiburn
Harry Briggs, Managing Director, OMERS Ventures
Linisha Palm, CEO, We.Care
Steve Tolle, General Partner, HLM Venture Partners

Georgi Natchev, CEO, DigiburnHarry Briggs, Managing Director, OMERS VenturesLinisha Palm, CEO, We.Care Steve Tolle, Partner, HLM Ventures-1


15:20 Closing Keynote Panel: How do we build trust in Digital Technology, AI and Data Use?

  • Ethical data usage in an era of digital technology and regulation
  • The patient as the ultimate data owner
  • Engaging the patient in genuine dialogue to build trust in a new digital world

Mark Davies, Chief Medical Officer, IBM
Liz Ashall-Payne, CEO & Co-Founder, ORCHA Healthcare
Natalie Banner, Director of Ethics, Genomics England

Mark Davies, Chief Medical Officer, IBMLiz Ashall-Payne, CEO and Co-Founder, ORCHA HealthcareNatalie Banner, Director of Ethics, Genomics England


16:00 Close of Congress